Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

The GLP-1 drug market is projected to reach $185 billion by 2033. Eli Lilly dominates with its successful Mounjaro and Zepbound drugs generating $13 billion in Q1 revenue, but trades at a premium 39x earnings. Viking Therapeutics, a smaller biotech with no approved products yet, offers higher risk/reward potential with its promising VK2735 candidate in phase 3 trials. The author recommends Viking as the better buy for risk-tolerant investors seeking significant upside.